{"entity":{"id":"da-lecanemab","kind":"drug","name":"Lecanemab","aka":[],"tldr":"Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure.","summary":"US labeling supports starting in mild cognitive impairment or mild dementia of the Alzheimer’s type after amyloid confirmation. Infusions are typically every two weeks. MRI monitoring and an individual bleeding-risk discussion are essential. It does not restore lost function.","status":"approved","asOf":"2026-09-21","links":[{"label":"FDA traditional approval","url":"https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease","mild-cognitive-impairment"],"sections":[],"technologies":[],"targets":["da-target-amyloid-beta"],"drugs":[],"companies":["da-eisai","da-biogen"],"institutions":[],"pathways":[],"terms":["da-term-aria"],"trials":["da-trial-clarity-ad"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Leqembi","code":"BAN2401","modality":"mAb","mechanism":"Amyloid-beta–directed antibody that reduces plaques.","approvals":[{"region":"US","year":2023,"indication":"Early Alzheimer’s disease with confirmed amyloid"},{"region":"JP","year":2023,"indication":"Early Alzheimer’s disease"},{"region":"CN","year":2024,"indication":"Early Alzheimer’s disease"},{"region":"UK","year":2024,"indication":"Licensed; funding decisions are separate from the licence"},{"region":"EU","year":2025,"indication":"Authorisation pathway; national access varies"},{"region":"AU","year":2025,"indication":"Regulatory review or access may lag the US label"}],"mechanismSteps":[],"toxicity":[],"access":[{"country":"US","reimbursement":"Coverage depends on plan, registry, and site capability","source":"https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval","asOf":"2026-09-21"},{"country":"UK","reimbursement":"A licence is not the same as NHS commissioning","source":"https://www.nice.org.uk/guidance/ng97","asOf":"2026-09-21"}],"regulatoryEvents":[]},"route":"/drugs/da-lecanemab/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"},{"id":"mild-cognitive-impairment","kind":"cancer","name":"Mild cognitive impairment","route":"/diagnoses/mild-cognitive-impairment/"}],"target":[{"id":"da-target-amyloid-beta","kind":"target","name":"Amyloid-beta","route":"/targets/da-target-amyloid-beta/"}],"company":[{"id":"da-biogen","kind":"company","name":"Biogen","route":"/companies/da-biogen/"},{"id":"da-eisai","kind":"company","name":"Eisai","route":"/companies/da-eisai/"}],"term":[{"id":"da-term-aria","kind":"term","name":"ARIA","route":"/terms/da-term-aria/"}],"trial":[{"id":"da-trial-clarity-ad","kind":"trial","name":"CLARITY AD","route":"/trials/da-trial-clarity-ad/"}],"section":[{"id":"da-front-anti-amyloid","kind":"section","name":"Anti-amyloid treatment","route":"/fronts/da-front-anti-amyloid/"}],"technology":[{"id":"da-tech-anti-amyloid-mab","kind":"technology","name":"Anti-amyloid antibodies","route":"/technologies/da-tech-anti-amyloid-mab/"},{"id":"da-tech-apoe-testing","kind":"technology","name":"ApoE testing","route":"/technologies/da-tech-apoe-testing/"}],"pairing":[{"id":"da-pair-lecanemab-mri","kind":"pairing","name":"Lecanemab with MRI monitoring","route":"/pairings/da-pair-lecanemab-mri/"}],"paper":[{"id":"da-paper-clarity-ad","kind":"paper","name":"Lecanemab in Early Alzheimer’s Disease (CLARITY AD)","route":"/key-papers/da-paper-clarity-ad/"}],"idea":[{"id":"da-idea-inclusive-anti-amyloid-trials","kind":"idea","name":"Antibody trials that enrol mixed and comorbid disease","route":"/ideas/da-idea-inclusive-anti-amyloid-trials/"}],"roadmap":[{"id":"da-roadmap-anti-amyloid","kind":"roadmap","name":"Anti-amyloid medicines","route":"/roadmaps/da-roadmap-anti-amyloid/"}]}}